#Australia #Melbourne #Lateral Pharma #neuropathic pain #LanCL1

Lateral Pharma's Breakthrough in Neuropathic Pain Treatment

Lateral Pharma, an Australian biotechnology company, has recently made headlines with a significant publication in the peer-reviewed journal PAIN, which focuses on pain research. The study highlights a novel and promising target for neuropathic pain therapies: Lanthionine Synthetase C-Like Protein 1 (LanCL1). This advancement represents a crucial step forward in understanding and potentially alleviating the suffering of millions globally affected by neuropathic pain, a condition that often arises from diabetes, injury, chemotherapy, or viral infections.

Understanding the Challenge of Neuropathic Pain

Neuropathic pain is a debilitating condition affecting approximately 10% of the global population. Current treatment options are inadequate for many patients, with about half not experiencing relief from existing therapies, which often come with severe side effects or limitations in dosability. Therefore, new treatments are not just welcomed but desperately needed.

Lateral Pharma's focus on SCP (Stressed Cell Protectant) drugs demonstrates a refreshing approach. Their latest publication reveals that SCP drugs, including the first-generation peptide LAT8881, show promising activity through the LanCL1 pathway. This discovery sheds light on the biological mechanisms underlying neuropathic pain, offering a potential shift in therapeutic strategy.

Publication Highlights

David Kenley, CEO of Lateral Pharma, emphasized the importance of this research: "This publication marks a pivotal milestone in advancing the biology of neuropathic pain and accelerating Lateral Pharma's mission. By identifying LanCL1 as a novel therapeutic target, we are making strides toward addressing unmet medical needs in this area."

The publication also dovetails with findings from Lateral Pharma's Phase 1b study involving patients with chronic lumbar radicular pain (sciatica). In this cohort, a single intravenous dose of LAT8881 was noted to be safe and well-tolerated, with significant reductions in provoked pain observed, further validating the SCP drugs' potential.

In addition to the breakthroughs related to neuropathic pain, complementary research on LAT9997, another SCP peptide from Lateral Pharma, yielded promising results in preclinical models of influenza-associated bacterial pneumonia. The administration of LAT9997 not only enhanced survival rates from a grim 0% in control subjects to an impressive 85% in treated groups but also demonstrated its broader therapeutic potential beyond neuropathic pain treatments.

Intellectual Property Advances

The progress of Lateral Pharma in the pharmaceutical landscape is bolstered by a strong intellectual property portfolio, which includes a granted USPTO patent covering the composition of LAT9997 specifically for treating neuropathic pain.

Conclusion

Overall, Lateral Pharma's research not only propels the understanding of neuropathic pain treatments but also strengthens the case for SCP therapeutics as a revolutionary approach in medicine. The combined insights from these dual studies provide an exciting outlook on future therapies aimed at these challenging medical conditions, reinforcing Lateral Pharma's commitment to advancing healthcare solutions for those in need. As more research unfolds, the therapeutic landscape for neuropathic pain may be on the verge of transformation, thanks to innovative strategies targeting LanCL pathways.

For those interested in exploring more about this research, the publication, titled Lanthionine synthetase C-like protein 1 (LanCL1) a therapeutic target for neuropathic pain, is now available online through PAIN. More insights can be anticipated as the Lateral Pharma research team continues to unveil new data and treatments aimed at improving patient lives.